Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019046611) PHARMACEUTICAL DOSAGE FORMS
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/046611 International Application No.: PCT/US2018/048904
Publication Date: 07.03.2019 International Filing Date: 30.08.2018
IPC:
A61K 31/135 (2006.01) ,A61K 9/20 (2006.01) ,A61K 9/22 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
13
Amines, e.g. amantadine
135
having aromatic rings, e.g. methadone
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9
Medicinal preparations characterised by special physical form
20
Pills, lozenges or tablets
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9
Medicinal preparations characterised by special physical form
20
Pills, lozenges or tablets
22
Sustained or differential release type
Applicants:
PURDUE PHARMA L.P. [US/US]; One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901, US
Inventors:
AKCAN, Ozgur; US
MANNION, Richard; US
Agent:
YANG, Weiying; US
Priority Data:
62/552,52131.08.2017US
Title (EN) PHARMACEUTICAL DOSAGE FORMS
(FR) FORMES POSOLOGIQUES PHARMACEUTIQUES
Abstract:
(EN) The invention relates to a solid oral extended release pharmaceutical dosage form comprising an extended release matrix formulation. The extended release matrix fomiulation comprises (1) at least one active agent, (2) at least one anionic surfactant, and (3) at least about 40% by weight (based on the weight of the extended release matrix formulation) of at least one polyethylene oxide. In certain embodiments, the molar ratio of the at least one anionic surfactant to the at least one active agent is from about 1 :2 to about 10: 1.
(FR) L'invention concerne une forme posologique pharmaceutique solide à libération prolongée orale comprenant une formulation de matrice à libération prolongée. La formulation de matrice à libération prolongée comprend (1) au moins un agent actif, (2) au moins un tensioactif anionique et (3) au moins environ 40 % en poids (sur la base du poids de la formulation de matrice à libération prolongée) d'au moins un oxyde de polyéthylène. Dans certains modes de réalisation, le rapport molaire du ou des tensioactifs anioniques sur le ou les agents actifs est d'environ 1:2 à environ 10:1.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)